2025 Tianjin International Breast Cancer Conference |Professor Zhang Juliang: Skip the “Grand Narrative”—Even Small Questions Can Lead to Big Papers! Expert Advice on How Early- and Mid-Career Doctors Can Break Through With IITs

2025 Tianjin International Breast Cancer Conference |Professor Zhang Juliang: Skip the “Grand Narrative”—Even Small Questions Can Lead to Big Papers! Expert Advice on How Early- and Mid-Career Doctors Can Break Through With IITs

From “following evidence” to “creating evidence”, clinical research in breast cancer in China is entering a deep phase of high-quality development. Within the grand framework of precision medicine, industry-sponsored trials (ISTs) may serve as the gateway for innovative drugs to enter clinical practice, but investigator-initiated trials (IITs) are the master key to solving the “last mile” problems of real-world clinical application.
SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a reanalysis of the landmark NSABP B-20 trial (Abstract No. RF3-03) was presented, exploring the prognostic value and chemotherapy benefit–predictive potential of a multimodal artificial intelligence (MMAI) model based on digital pathology and clinical data in hormone receptor–positive (HR+), node-negative early breast cancer.
SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study based on data from the NSABP B-42 and TAILORx trials (Abstract No. RF3-07) reported the development and validation of a multimodal, multitask deep learning model (Clarity BCR). By integrating routine digital pathology images with key clinical variables, this model accurately predicts the risk of late distant recurrence (late DR) in patients with hormone receptor–positive (HR+) early breast cancer and effectively identifies those who may benefit from extended endocrine therapy (EET).
SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study titled “Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. The study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early triple-negative breast cancer (TNBC), revealing the predictive value of tumor-infiltrating lymphocytes (TILs) and molecular TNBC subtypes for treatment efficacy.
SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.
SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.